Cancer/Tumor Profiling Market to be Worth $22.3 Billion by 2030

Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO) – Global Forecast to 2030

The Cancer/Tumor Profiling Market is projected to reach $22.3 billion by 2030, at a CAGR of 10.8% from 2023 to 2030. The rise in cancer cases, the growing research of novel molecules, and the increasing number of genomic research projects have increased the demand for cancer/tumor profiling in current use. The emergence of tumor profiling has removed the restraints of traditional cancer/tumor classification approaches, which rely on the morphology of the cancerous cells and the surrounding tissues. Today, cancer/tumor profiling is accepted as the standard technique for classifying tumors, with the guidelines associated with the European Society for Molecular Oncology (ESMO) and the College of American Pathologists (CAP).

The profiling of tumors with advanced technologies such as ISH, NGS, IHC, and PCR has successfully analyzed the genes, amplicons, and gene regions with familiar involvement with tumors. This approach, also known as targeted treatment, delivers high sensitivity for detecting tumor subclones or rare mutations, providing increased visibility regarding important mutations acting as drivers of cancer.